Design optimization for clinical trials in early-stage manifest Huntington's disease. (2017)
Attributed to:
Targeting the innate immune system in Huntington's disease
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/mds.27122
PubMed Identifier: 28906031
Publication URI: http://europepmc.org/abstract/MED/28906031
Type: Journal Article/Review
Volume: 32
Parent Publication: Movement disorders : official journal of the Movement Disorder Society
Issue: 11
ISSN: 0885-3185